Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/216729CELLULAR VACCINE PLATFORM AND METHODS OF USE
WO 28.10.2021
Int.Class A61K 39/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
Appl.No PCT/US2021/028427 Applicant INTIMA BIOSCIENCE, INC. Inventor CHOUDHRY, Modassir
Cellular vaccine platforms, such as vaccine immune viral opsonization platforms, for eliciting host immune responses are disclosed. Also disclosed are the methods of making and using the cellular vaccine platforms in stimulating host immune responses.
2.WO/2022/016071VIRAL DETECTION SYSTEMS AND USES THEREOF
WO 20.01.2022
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
Appl.No PCT/US2021/042008 Applicant TRUSTEES OF BOSTON UNIVERSITY Inventor SANKAR, Karthika
The systems, methods, devices and kits disclosed herein be used to determine the presence and/or level a target analyte(s) in a biological sample, wherein the analyte(s) is associated with a pathogenic (e.g., a viral antigen or whole virus) or otherwise altered physiological condition (e.g., pregnancy). In certain embodiments, the systems, methods, devices and kits provide one or more improved properties relative to the RT-PCT and lateral flow antibody assays known in the art for the detection of SARS-CoV-2, including but not limited to, assay time, ease of use, risk of infection, accuracy, specificity, selectivity, limit of detection of the assay, quantitative detection and the effect of common interferents to the sensor output, cost, simplicity or a combination thereof.
3.WO/2022/023734CORONAVIRAL PACKAGING SIGNALS
WO 03.02.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/GB2021/051934 Applicant UNIVERSITY OF LEEDS Inventor CLARK, Sam
The present invention relates to virus like particles, vaccines and delivery vectors utilising coronavirus packaging signals, and therapeutic agents targeting such packaging signals.
4.WO/2022/036366REDUCTION OF COVID-19 COAGULOPATHY AND OTHER INFLAMMATION-ASSOCIATED COAGULOPATHIES BY ADMINISTRATION OF FIBROBLASTS
WO 17.02.2022
Int.Class C07K 14/50
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
50Fibroblast growth factor (FGF)
Appl.No PCT/US2021/071163 Applicant FIGENE, LLC Inventor O'HEERON, Pete
Embodiments of the disclosure include methods and compositions for treatment or reduction in risk of coagulopathy of any kind, including associated with inflammation. In specific embodiments, the coagulopathy is associated with upregulated production of tissue factor in the individual. In specific embodiments, the coagulopathy is in an individual that has SARS-CoV-2 infection or is at risk for having SARS-CoV-2 infection. In specific embodiments, the methods and compositions include fibroblasts, and/or modified fibroblasts, and/or derivatives of fibroblasts, including those fibroblasts exposed to TNF-alpha or one or more other inflammatory agents before activation of the fibroblasts.
5.WO/2021/243149PROTEIN COVARIANCE NETWORKS REVEAL INTERACTIONS IMPORTANT TO THE EMERGENCE OF SARS CORONAVIRUSES AS HUMAN PATHOGENS
WO 02.12.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/034753 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor MEKALANOS, John, J.
The methods and compositions provided herein, relate in part, to the discovery of conserved interactions between amino acid residues in all proteins encoded by SARS-CoV-related viruses. Accordingly, pairs and networks of residue variants that exhibited statistically high frequencies of covariance with each other can be used as a new computational approach (Covariance-based Phylogeny Analysis) for understanding viral evolution and adaptation. Provided herein is evidence that the evolutionary processes that converted a bat virus into a human pathogen occurred through recombination with other viruses in combination with new adaptive mutations important for entry into human cells.
6.WO/2021/178661COMPOSITIONS CONTAINING A PATHOGENIC ANTIGEN AND AN IMMUNE STIMULATOR
WO 10.09.2021
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2021/020863 Applicant ONCOSEC MEDICAL INCORPORATED Inventor MUKHOPADHYAY, Anandaroop
Described are compositions comprising a pathogenic antigen and an immune stimulator for use in inducing an immune response to a pathogen. Also described are compositions comprising an immunostimulatory cytokine and a pathogenic antigen for use in treating cancer.
7.WO/2021/183887SYSTEMS AND METHODS FOR VIRAL GENOME TARGETING
WO 16.09.2021
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/US2021/022107 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor QI, Lei S.
Described herein are systems for targeting viral genomes. Also described herein are methods for targeting viral genomes utilizing the systems described in the instant disclosure. In some cases, systems and methods disclosed herein can be used to treat viral infections. In preferred embodiments, the systems utilise a CRISPR/Cas13d complex to target the genome of an RNA virus such as coronavirus or influenza virus.
8.WO/2021/198326ASSAYS FOR THE DETECTION OF SARS-COV-2
WO 07.10.2021
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No PCT/EP2021/058426 Applicant DIASORIN S.P.A. Inventor BRAMBATI, Chiara
The present invention is directed to methods for assaying for the presence of SARS-CoV-2 in a sample, including a clinical sample, and to oligonucleotides, reagents and kits useful in such assays. In particular, the present invention is directed to such assays that are rapid, accurate and specific for the detection of SARS-CoV-2 using labeled oligonucleotides hybridizing to the ORFlab and/or S gene.
9.WO/2022/043400NUCLEIC ACIDS ENCODING A POLYPEPTIDE COMPRISING A MODIFIED FC REGION OF A HUMAN IGG1 AND AT LEAST ONE HETEROLOGOUS ANTIGEN
WO 03.03.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/EP2021/073542 Applicant SCANCELL LIMITED Inventor DURRANT, Linda Gillian
The present invention relates to nucleic acids and peptides encoded by those nucleic acids. In particular, the peptides comprise a modified IgG1 Fc region and one or more heterologous epitopes, which may be B- or T-cell epitopes. A nucleic acid of the invention may encode a polypeptide comprising: (i) a modified Fc region of a human IgG1, and (i) at least one heterologous antigen, wherein (a) the modified Fc region comprises at least the part of Fc that is capable of binding to CD64 and/or TRIM21, (b) at least one residue of the Fc region is modified to the corresponding residue from a mouse IgG3 antibody and (c) the modified Fc region has enhanced avidity for Fc- gamma receptor (FcγR) when compared to the corresponding wildtype Fc region.
10.20210393769CORONAVIRUS VACCINE AND METHODS OF USE THEREOF
US 23.12.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17341928 Applicant Davinder Gill Inventor Davinder Gill

An immunogenic composition effective for eliciting an immune response against cells that present coronavirus S protein and/or coronavirus M protein derived antigens on a virus-like-particle (VLP) system. In a method embodiment, the antigen presenting VLP is administered to a mammal, such as a human, to elicit an immune response against coronavirus S protein and/or coronavirus M protein. A preferred method embodiment may include at least one additional dose of immunogenic composition to enhance the immune response effectiveness of the coronavirus vaccine.